Analysis stagea | Sensitivity (95% CI) | Specificity (95%CI) | PPV (95% CI) | NPV (95% CI) | AUC (95% CI) | OR (95% CI) | Percentage variance (R2 × 100) |
---|---|---|---|---|---|---|---|
Stage i) Application of Cohort DAHL | 36.4% (20.4 to 54.9) | 84.7% (82.7 to 86.5) | 5.2% (3.3 to 8.0) | 98.3% (97.8 to 98.7) | 0.52 (0.48 to 0.56) | 3.16 (1.5 to 6.5) | 1% |
Stage ii) Application of Improved Cohort DAHL | 46.8% (40.2 to 53.7) | 90.3% (88.5 to 92.0) | 48.1% 42.5 to 53.8) | 89.9% (88.6 to 90.9) | 0.69 (0.65 to 0.73) | 8.26 (5.9 to 11.5) | 18.4% |
Stage iv) Application of the GP-HLA | 40.1% (33.9 to 46.6) | 88.6% (86.7 to 90.3) | 40.3% (35.1 to 45.6) | 88.5% (87.4 to 89.5) | 0.64 (0.60 to 0.69) | 5.18 (3.8 to 7.1) | 11.2% |